| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC0013 |
| Trial ID | NCT00063934 |
| Disease | Breast Cancer |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | doxorubicin hydrochloride|docetaxel|filgrastim|pegfilgrastim|therapeutic conventional surgery |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer |
| Year | 2003 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2012-02885|NCI-2012-02885|6023|DM02-700|6023|P30CA016672|N01CM17003 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||